中国实用儿科杂志2026，Vol.41Issue(8)：650-653,4.DOI:10.19538/j.ek2026080607
Janus激酶抑制剂在儿童风湿免疫性疾病中的应用
Janus kinase inhibitors in pediatric rheumatic and immune diseases
摘要
Abstract
Janus kinase inhibitors provide a new therapeutic option distinct from conventional immunosuppressants and single-target biologics for pediatric rheumatic and immune diseases by modulating multiple cytokine signals through the JAK-STAT pathway.Currently,there have been clear evidence of randomized controlled trials for tofacitinib and baricitinib in non-systemic juvenile idiopathic arthritis,while evidence for upadacitinib in polyarticular juvenile idiopathic arthritis is accumulating.In juvenile dermatomyositis,JAK inhibitors may be considered as individualized targeted therapeutic options for patients with refractory disease or specific phenotypes,particularly for children with prominent cutaneous involvement,marked type Ⅰ interferon activation,or concomitant interstitial lung disease.In childhood-onset systemic lupus erythematosus,their use remains mainly confined to refractory,relapsing,steroid-dependent or specific hyperinflammatory phenotypes.Besides,JAK inhibitors can also be used in type Ⅰ interferonopathies and macrophage activation syndrome secondary to rheumatic and immune diseases.Clinical application of JAK inhibitors should be guided by stratified decision-making based on disease phenotype,inflammatory pathways,previous treatment response and individual risk profiles.In the future,their use in child patients should focus on monitoring of blood drug concentration and precise adjustment of individualized dose.关键词
JAK抑制剂/儿童/风湿免疫性疾病/血药浓度监测Key words
JAK inhibitors/child/rheumatic and immune disorders/blood drug concentration monitoring分类
医药卫生引用本文复制引用
周煜,马明圣..Janus激酶抑制剂在儿童风湿免疫性疾病中的应用[J].中国实用儿科杂志,2026,41(8):650-653,4.基金项目
协和人才培育计划C类项目(UBJ10837) （UBJ10837）
